U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984497) titled 'Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD' on May 12.
Brief Summary: Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury.
Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used ...